1. Clinical & Scientific Overview
Magnesium Sulphate Injection (Parenteral IV/IM Pritchard & Zuspan Eclampsia Regimen) (TIP-MED-000248, Reference Code [12.16]) is classified under
Obstetric, Gynaecological & Antifibrinolytic Medicines (Ch 12) as a Parenteral Anticonvulsant in Eclampsia, Electrolyte Replenisher & Antiarrhythmic (Physiological Calcium Antagonist & NMDA Blocker).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.16], p. 162): Magneon, MgSO4 Injection (50% w/v) — Strengths & Dosage Forms: Injection: 50% w/v (500 mg/mL = ~2 mmol Mg2+/mL) in 2 mL (1 g) and 10 mL (5 g) ampoules.
Injection: 50% w/v (500 mg/mL = ~2 mmol Mg2+/mL) in 2 mL (1 g) and 10 mL (5 g) ampoules.
3. Mechanism of Action & Pharmacodynamics
Blocks neuronal N-methyl-D-aspartate (NMDA) glutamate receptors centrally, vasodilates cerebral arterioles, and inhibits acetylcholine release at the neuromuscular junction by competing with calcium influx.
4. Therapeutic Indications & Evidence-Supported Uses
- Prevention and control of seizures in severe pre-eclampsia and eclampsia (Pritchard / Zuspan regimens)
- Torsades de Pointes polymorphic VT
- acute severe life-threatening asthma refractory to bronchodilators
- severe hypomagnesaemia
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adult: Eclampsia (Pritchard IM/IV Regimen): Loading 4 g IV (diluted to 20% over 5-15 min) + 10 g deep IM (5 g in each buttock with 1 mL 2% Lignocaine), then 5 g deep IM q4h in alternate buttocks for 24h after last seizure/delivery. Zuspan IV Regimen: 4 g IV over 15-20 min, then 1 g/hour IV infusion. Torsades / Severe Asthma: 2 g IV over 10-20 min. • Paediatric: Acute Severe Asthma / Torsades: 25-50 mg/kg IV (max 2 g) diluted and infused over 20 min.
Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Excreted 100% by kidneys! If urine output <25-30 mL/hour (or <100 mL in 4 hours), GIVE THE LOADING DOSE (4 g IV) ONLY and WITHHOLD or halve maintenance doses strictly guided by patellar reflexes and serum magnesium. • Hepatic: No hepatic adjustment required.
Renal: Excreted 100% by kidneys! If urine output <25-30 mL/hour (or <100 mL in 4 hours), GIVE THE LOADING DOSE (4 g IV) ONLY and WITHHOLD or halve maintenance doses strictly guided by patellar reflexes and serum magnesium. • Hepatic: No hepatic adjustment required.
Renal: Excreted 100% by kidneys! If urine output <25-30 mL/hour (or <100 mL in 4 hours), GIVE THE LOADING DOSE (4 g IV) ONLY and WITHHOLD or halve maintenance doses strictly guided by patellar reflexes and serum magnesium. • Hepatic: No hepatic adjustment required.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindications: Myasthenia gravis; heart block or severe myocardial damage; anuria (for maintenance doses). • Precautions: HIGH-ALERT OBSTETRIC ELECTROLYTE: Therapeutic eclampsia serum Mg2+ = 2.0–3.5 mmol/L (4–7 mEq/L); Loss of patellar knee-jerk reflex occurs at >3.5–5.0 mmol/L (8–10 mEq/L); Respiratory paralysis at >5.0–6.5 mmol/L (12 mEq/L); Cardiac arrest at >10–12.5 mmol/L (25 mEq/L). Always keep CALCIUM GLUCONATE 10% (10 mL = 1 g IV over 3-5 min) at the bedside as the immediate physiological antidote!
Key Clinical Precautions: Renal: Excreted 100% by kidneys! If urine output <25-30 mL/hour (or <100 mL in 4 hours), GIVE THE LOADING DOSE (4 g IV) ONLY and WITHHOLD or halve maintenance doses strictly guided by patellar reflexes and serum magnesium. • Hepatic: No hepatic adjustment required.
8. Adverse Effects Profile
- Flushing, intense warmth, sweating, pain at IM site, nausea.
- Loss of deep tendon reflexes, respiratory depression/apnoea, hypotension, bradycardia, heart block, cardiac arrest.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Nifedipine / Calcium channel blockers -> additive hypotension and neuromuscular weakness; Neuromuscular blockers (Vecuronium, Rocuronium, Succinylcholine) -> markedly prolonged paralysis; Aminoglycosides -> additive neuromuscular blockade
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Inform patient that a strong wave of body heat and flushing during the IV injection is normal; report difficulty breathing or extreme weakness immediately.
- Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Injection: 50% w/v (500 mg/mL = ~2 mmol Mg2+/mL) in 2 mL (1 g) and 10 mL (5 g) ampoules.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.16] (p. 162)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.17] Oxytocin, Methylergometrine Maleate & Carboprost — High-Alert Obstetric Uterotonics (Neurohypophyseal Peptide, Ergot
- [12.16]-CMP163 Isoxsuprine Hydrochloride IP — Parenteral Anticonvulsant in Eclampsia, Electrolyte Replenisher &
- [12.17]-C164 Methylergometrine Maleate — High-Alert Obstetric Uterotonics (Neurohypophyseal Peptide, Ergot
- [12.17]-C165 Carboprost Tromethamine — High-Alert Obstetric Uterotonics (Neurohypophyseal Peptide, Ergot